Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

(2020) Keith W. Pratz et al.   BLOOD

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

(2020) Shanshan Pei et al.   Cancer Discovery

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

(2020) Ing S. Tiong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemia

(2020) Ibrahim Aldoss et al.   AMERICAN JOURNAL OF HEMATOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant

(2020) Prashant Sharma et al.   Blood Advances

Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia

(2020) Karamjeet S. Sandhu et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia

(2020) Shukaib Arslan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification

(2019) Mohamed L. Sorror et al.   JAMA Oncology

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

(2019) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2018) Dalila Salvatore et al.   HAEMATOLOGICA

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2018) Dalila Salvatore et al.   HAEMATOLOGICA

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

(2018) Courtney L. Jones et al.   CANCER CELL

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

(2017) Mohamed L. Sorror et al.   JAMA Oncology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression

(2016) T.-C. Ho et al.   BLOOD

Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation

(2016) J A Gutman et al.   BONE MARROW TRANSPLANTATION

Cord-Blood Transplantation in Patients with Minimal Residual Disease

(2016) Filippo Milano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study

(2015) Mohamed L. Sorror et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML

(2015) T. N. Wong et al.   BLOOD

Clinical significance ofin vivocytarabine-induced gene expression signature in AML

(2015) Jatinder K. Lamba et al.   LEUKEMIA & LYMPHOMA

Outcome of older patients with acute myeloid leukemia

(2013) Mya S. Thein et al.   CANCER

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE